Aclaris Therapeutics Shares Tumble Following Quarterly Report

Aclaris Therapeutics witnessed a significant selloff in its stock price after releasing disappointing third-quarter 2025 financial results. The biotechnology firm reported a net loss of $14.6 million, representing nearly double the $7.6 million loss recorded during the same period last year. Revenue also declined substantially, falling to $3.3 million from the previous year’s $4.3 million. These figures indicate a notable acceleration in the company’s operational cash burn rate.

Investors responded decisively to the financial update, driving shares down more than 8% to $2.13. The stock has declined 14% year-to-date, maintaining extreme volatility throughout the past twelve months with trading ranging between $5.17 and $1.05. While the company maintains $167 million in liquidity, projected to fund operations through 2028, management’s credibility Read more...